67-92-5CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1CURUTKGFNZGFSE-UHFFFAOYSA-NDicyclomine is the ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome. It has a role as a muscarinic antagonist, a parasympatholytic and an antispasmodic drug. It is a tertiary amine and a carboxylic ester. It is functionally related to a 2-diethylaminoethanol and a 1,1'-bi(cyclohexyl)-1-carboxylic acid.
67-92-5、77-19-0Pharmaceuticals -> Listed in ZINC15
Pharmaceuticals
SOL IN WATER ABOUT 25% /HYDROCHLORIDE/
1 G IN 13 ML WATER, 5 ML ALC, 2.5 ML CHLOROFORM, 770 ML ETHER; INSOL IN ALKALINE AQ MEDIUM /HCL/
3.27e-03 g/L
MP 164-166 °C /HYDROCHLORIDE/
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
SIDE EFFECTS OF DICYCLOMINE INCL DIZZINESS, FEELING OF ABDOMINAL FULLNESS, & DRY MOUTH. CONSTIPATION, BLURRED VISION, FATIGUE, SEDATION, NAUSEA, VOMITING, HEADACHE, IMPOTENCE, URINARY RETENTION, & RASH OCCUR RARELY.
THERE IS ONE REPORT THAT WHEN PT UNDER TREATMENT FOR GLAUCOMA OF UNSPECIFIED TYPE WERE GIVEN 10 MG OF DICYCLOVERINE HYDROCHLORIDE ORALLY, THEY HAD RISE OF 3-10 MM HG FOR 2-3 HR. IN MOST CASES NO RISE OF OCULAR PRESSURE HAS BEEN FOUND, REGARDLESS OF TYPE OF GLAUCOMA. /HYDROCHLORIDE/
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
Dicyclomine is an anticholinergic drug used to relax the smooth muscles of the intestines. It's duration of action is not especially long as it is usually taken 4 times daily with individual doses of 20-40mg orally or 10-20mg by intramuscular injection. Dicyclomine should not be administered intravenously.
Dicyclomine achieves its action partially through direct antimuscarinic activity of the M1, M3, and M2 receptors; and partially through antagonism of bradykinin and histamine. Dicyclomine non-competitively inhibits the action of bradykinin and histamine, resulting in direct action on the smooth muscle, and decreased strength of contractions seen in spasms of the ileum.
...MAJOR ACTION APPEARS TO BE NONSPECIFIC DIRECT RELAXANT ACTION ON SMOOTH MUSLCE RATHER THAN COMPETITIVE ANTAGONISM OF ACH.
4KV4X8IF6V
DICYCLOMINE
Established Pharmacologic Class [EPC] - Anticholinergic
Mechanisms of Action [MoA] - Cholinergic Antagonists
Dicyclomine is an Anticholinergic. The mechanism of action of dicyclomine is as a Cholinergic Antagonist.
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…
DTXSID1022926CHEMBL1123CHEBI:4514PRACTICALLY ODORLESS & HAS VERY BITTER TASTE /HYDROCHLORIDE/
CRYSTALS FROM BUTANONE /HYDROCHLORIDE/
FINE, WHITE, CRYSTALLINE POWDER /HYDROCHLORIDE/
INCIDENCE OF BIRTH DEFECTS IN OFFSPRING OF WOMEN WHO TOOK BENDECTIN CONTAINING 10 MG DICYCLOMINE HCL DURING PREGNANCY WAS INVESTIGATED. BIRTHS WERE TRACED FOR 2,298 PT & INCIDENCE OF DEFECTS COMPARED WITH THOSE IN RELEVANT POPULATIONS. NO EVIDENCE OF TERATOGENICITY FOUND.
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
dicyclomine
DILI Negative
Oral
DOI:10.1016/j.drudis.2019.09.022
Dicyclomine
1.9
7.9
The recommended initial dose is 20 mg four times a day. After one week treatment with the initial dose, the dose may be increased to 40 mg four times a day unless side effects limit dosage escalation.
Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 80 mg/day, Lowest Therapeutic Dose (LTD): 1.0 mg/kg-day, and Screening Dose: 0.0003 mg/kg-day.
31-May-18
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
The bioavailability of dicyclomine has not been determined, though it is likely well absorbed as the primary route of elimination is in the urine. Dicyclomine has a Tmax of 1-1.5h.
Dicyclomine is 79.5% eliminated in the urine and 8.4% in the feces.
The volume of distribution for a 20mg oral dose is 3.65L/kg.
Data regarding the clearance of dicyclomine is not readily available.
MEDICATION
Use (kg) in USA (2002): 2250
US PATENT 2,474,796. /HYDROCHLORIDE/
PREPD FROM 1-CYCLOHEXYLCYCLOHEXYL CYANIDE BY ALCOHOLYSIS & ESTERIFICATION... /HYDROCHLORIDE/
VerwendenAnticholinergic.
DefinitionChEBI: The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularl that associated with irritable bowel syndrome.